Retraction: Progesterone and Src Family Inhibitor PP1 Synergistically Inhibit Cell Migration and Invasion of Human Basal Phenotype Breast Cancer Cells (BioMed Research International (2015) 2015 (14) DOI: 10.1155/2015/426429);Progesterone and Src family inhibitor PP1 synergistically inhibit cell migration and invasion of human basal phenotype breast cancer cells

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Xie, Mingxuan ^a,b   Zhou, Li ^b,c   Chen, Xi ^a   Gainey, Lindsey O ^b   Xiao, Jian ^a   Nanes, Mark S ^d   Hou, Anji ^c   You, Shaojin ^b   Chen, Qiong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c SHANGHAI SEVENTH PEOPLE S HOSPITAL   (China)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ACTIVATED POTASSIUM CHANNEL SUBUNIT ALPHA 1; FOCAL ADHESION KINASE; GELATINASE B; MEMBRANE PROGESTERONE RECEPTOR ALPHA; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; 4-AMINO-5-(4-METHYLPHENYL)-7-(TERT-BUTYL)PYRAZOLO(3,4-D)PYRIMIDINE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGESTERONE; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84930966006     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2022/9810368     Document Type: Erratum

References (77)

1. M. T.Weigel andM. Dowsett, Current and emerging biomarkers in breast cancer: prognosis and prediction, Endocrine-Related Cancer, vol. 17, no. 4, pp. R245-R262, 2010.
2. X. Cui, R. Schiff, G. Arpino, C. K. Osborne, and A. V. Lee, Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy, Journal of Clinical Oncology, vol. 23, no. 30, pp. 7721-7735, 2005.
3. J. Alexieva-Figusch, H. A. vanGilse,W.C. J.Hop,C.H. Phoa, J. Blonk-van derWijst, and R. E. Treurniet, Progestin therapy in advanced breast cancer: megestrol acetate: an evaluation of 160 treated cases, Cancer, vol. 46, no. 11, pp. 2369-2372, 1980.
4. P. A. Johnson, H. Muss, P. Bonomi et al., Megestrol acetate as primary hormonal therapy for advanced breast cancer, Seminars in Oncology, vol. 15, supplement 1, no. 2, pp. 34-37, 1988.
5. R. Nishimura, K. Nagao, M. Matsuda et al., Predictive value of serum medroxyprogesterone acetate concentration forresponse in advanced or recurrent breast cancer, European Journal of Cancer Part A, vol. 33, no. 9, pp. 1407-1412, 1997.
6. S. Otani, N. Toyota, K. Nozaka et al., Successful combination therapy with 5-DFUR and MPA for breast cancer with spinal and vertebral metastases, Gan to Kagaku Ryoho, vol. 31, no. 13, pp. 2151-2153, 2004.
7. T.Otsuka,Y.Terashima, and S.Tashiro, Acase of long surviving advanced recurrent breast cancer withmultiple bone metastases responding to treatment with 5-DFUR combined with MPA, Gan To Kagaku Ryoho, vol. 29, no. 2, pp. 313-316, 2002.
8. R. Zaucha, K. Sosinska-Mielcarek, and J. Jassem, Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate, Breast, vol. 13, no. 4, pp. 321-324, 2004.
9. T. Toyama, H. Yamashita, Y. Hara, Y. Hikosaka, S. Kobayashi, and H. Iwase, Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment, International Journal of Clinical Oncology, vol. 6, no. 6, pp. 306-309, 2001.
10. H. Mio, A case of postoperative recurrent breast cancer with multiple lung metastases that completely responded to combination therapy of docetaxel (TXT) and medroxyprogesterone acetate (MPA), Cancer Chemotherapy, vol. 30, no. 7, pp. 985-988, 2003.
11. D. Generali, F. M. Buffa, A. Berruti et al., Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer, Journal of Clinical Oncology, vol. 27, no. 2, pp. 227-234, 2009.
12. P.Thomas, C. Tubbs, and V. F. Garry, Progestin functions in vertebrate gametes mediated by membrane progestin receptors (mPRs): Identification of mPR on human sperm and its association with spermmotility, Steroids, vol. 74, no. 7, pp. 614-621, 2009.
13. L. S. Cooper, C. E. Gillett, N. K. Patel, D. M. Barnes, and I. S. Fentiman, Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor, Cancer, vol. 86, no. 10, pp. 2053-2058, 1999.
14. Z. Saad,V. Bramwell, J. Duff et al., Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer, British Journal of Surgery, vol. 81, no. 2, pp. 217-220, 1994.
15. K. Bove, D. W. Lincoln, P. A. Wood, and W. J. M. Hrushesky, Fertility cycle influence on surgical breast cancer cure, Breast Cancer Research and Treatment, vol. 75, no. 1, pp. 65-72, 2002.
16. W. J.M.Hrushesky, S. A. Gruber, R. B. Sothern et al., Natural killer cell activity: age, estrous-and circadian-stage dependence and inverse correlation withmetastatic potential, Journal of the National Cancer Institute, vol. 80, no. 15, pp. 1232-1237, 1988.
17. L. Sivaraman and D. Medina, Hormone-induced protection against breast cancer, Journal of Mammary Gland Biology and Neoplasia, vol. 7, no. 1, pp. 77-92, 2002.
18. D. Medina, Mammary developmental fate and breast cancer risk, Endocrine-RelatedCancer, vol. 12,no. 3, pp.483-495, 2005.
19. J. E. Rossouw, G. L. Anderson, R. L. Prentice et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the womens health initiative randomized controlled trial, Journal of the American Medical Association, vol. 288, no. 3, pp. 321-333, 2002.
20. G. L. Anderson, M. Limacher, A. R. Assaf et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Womens Health Initiative randomized controlled trial, JAMA, vol. 291, no. 14, pp. 1701-1712, 2004.
21. C. A. Lange, J. K. Richer, and K. B. Horwitz, Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals, Molecular Endocrinology, vol. 13, no. 6, pp. 829-836, 1999.
22. E. M. McGowan, S. Saad, L. J. Bendall, K. F. Bradstock, and C. L. Clarke, Effect of progesterone receptor A predominance on breast cancer cell migration into bone marrow fibroblasts, Breast Cancer Research and Treatment, vol. 83,no. 3, pp. 211-220, 2004.
23. L. Zuo, W. Li, and S. You, Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway, Breast Cancer Research, vol. 12, article R34, 2010.
24. E. Karteris, S. Zervou, Y. Pang et al., Progesterone signaling in human myometrium through two novel membrane G proteincoupled receptors: potential role in functional progesterone withdrawal at term,Molecular Endocrinology, vol. 20, no. 7, pp. 1519-1534, 2006.
25. C. Tubbs and P. Thomas, Progestin signaling through an olfactory G protein and membrane progestin receptor-α in Atlantic croaker sperm: potential role in induction of sperm hypermotility, Endocrinology, vol. 150, no. 1, pp. 473-484, 2009.
26. V. Boonyaratanakornkit, E. McGowan, L. Sherman, M. A. Mancini, B. J. Cheskis, and D. P. Edwards, The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle, Molecular Endocrinology, vol. 21, no. 2, pp. 359-375, 2007.
27. G. R. Ehring, H. H. Kerschbaum, C. Eder et al., A nongenomic mechanism for progesterone-mediated immunosuppression: inhibition of K+ channels, Ca2+ signaling, and gene expression in T lymphocytes, The Journal of Experimental Medicine, vol. 188, no. 9, pp. 1593-1602, 1998.
28. R. Colomer, S. Montero, A. Lluch et al., Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer, Clinical Cancer Research, vol. 6, no. 6, pp. 2356-2362, 2000.
29. O.-K. Park-Sarge, T. G. Parmer, Y. Gu, and G. Gibori, Does the rat corpus luteum express the progesterone receptor gene? Endocrinology, vol. 136, no. 4, pp. 1537-1543, 1995.
30. P. Thomas, Y. Pang, J. Dong et al., Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor α subtypes and their evolutionary origins, Endocrinology, vol. 148, no. 2, pp. 705-718, 2007.
31. C. Dosiou, A. E. Hamilton, Y. Pang et al., Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone, Journal of Endocrinology, vol. 196, no. 1, pp. 67-77, 2008.
32. P. Thomas, Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions, Frontiers in Neuroendocrinology, vol. 29, no. 2, pp. 292-312, 2008.
33. G. E. Dressing and P. Thomas, Identification of membrane progestin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer, Steroids, vol. 72, no. 2, pp. 111-116, 2007.
34. E. Falkenstein, H.-C. Tillmann, M. Christ, M. Feuring, and M. Wehling, Multiple actions of steroid hormones-a focus on rapid, nongenomic effects, Pharmacological Reviews, vol. 52, no. 4, pp. 513-555, 2000.
35. R. Lösel and M. Wehling, Nongenomic actions of steroid hormones, Nature Reviews Molecular Cell Biology, vol. 4, no. 1, pp. 46-56, 2003.
36. R. Lösel, S. Breiter, M. Seyfert, M. Wehling, and E. Falkenstein, Classic and non-classic progesterone receptors are both expressed in human spermatozoa, Hormone and Metabolic Research, vol. 37, no. 1, pp. 10-14, 2005.
37. N. Sleiter, Y. Pang, C. Park et al., Progesterone receptor A (PRA) and PRB-independent effects of progesterone on gonadotropin-releasing hormone release, Endocrinology, vol. 150, no. 8, pp. 3833-3844, 2009.
38. Y. Zhu, C. D. Rice, Y. Pang, M. Pace, and P. Thomas, Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes, Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2231-2236, 2003.
39. W. Xu, X. Yuan, Y. J. Jung et al., The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation ofAKTin ErbB2 overexpressing breast cancer cells, Cancer Research, vol. 63, no. 22, pp. 7777-7784, 2003.
40. Y. Hirokawa, A. Levitzki, G. Lessene et al., Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors), Cancer Letters, vol. 245, no. 1-2, pp. 242-251, 2007.
41. A. C. Bishop, C.-Y. Kung, K. Shah, L. Witucki, K. M. Shokat, and Y. Liu, Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach, Journal of the American Chemical Society, vol. 121, no. 4, pp. 627-631, 1999.
42. S.Cleator,W.Heller, andR. C.Coombes, Triple-negative breast cancer: therapeutic options, The Lancet Oncology, vol. 8, no. 3, pp. 235-244, 2007.
43. N. U. Lin, E. Claus, J. Sohl, A. R. Razzak, A. Arnaout, and E. P. Winer, Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases, Cancer, vol. 113, no. 10, pp. 2638-2645, 2008.
44. R. M. Neve, K. Chin, J. Fridlyand et al., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes, Cancer Cell, vol. 10, no. 6, pp. 515-527, 2006.
45. Y. Kang, P. M. Siegel, W. Shu et al., A multigenic program mediating breast cancer metastasis to bone, Cancer Cell, vol. 3, no. 6, pp. 537-549, 2003.
46. A. J. Minn, G. P. Gupta, P. M. Siegel et al., Genes that mediate breast cancer metastasis to lung, Nature, vol. 436, no. 7050, pp. 518-524, 2005.
47. T. Yoneda, P. J. Williams, T. Hiraga,M.Niewolna, and R.Nishimura, A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro, Journal of Bone and Mineral Research, vol. 16, no. 8, pp. 1486-1495, 2001.
48. R. J.Weil, D. C. Palmieri, J. L. Bronder, A. M. Stark, and P. S. Steeg, Breast cancer metastasis to the central nervous system, The American Journal of Pathology, vol. 167, no. 4, pp. 913-920, 2005.
49. E. I. Chen, J. Hewel, J. S. Krueger et al., Adaptation of energy metabolism in breast cancer brainmetastases, Cancer Research, vol. 67, no. 4, pp. 1472-1486, 2007.
50. P. D. Bos, X. H. Zhang, C. Nadal et al., Genes that mediate breast cancer metastasis to the brain, Nature, vol. 459, no. 7249, pp. 1005-1009, 2009.
51. V. T. Ciavatta, M. Kim, P. Wong et al., Retinal expression of Fgf2 in RCS rats with subretinal microphotodiode array, Investigative Ophthalmology Visual Science, vol. 50, no. 10, pp. 4523-4530, 2009.
52. L. Min, Q. Chen, S. He, S. Liu, and Y. Ma, Hypoxia-induced increases in A549/CDDP cell drug resistance are reversed, Molecular Medicine Reports, vol. 5, no. 1, pp. 228-232, 2012.
53. N. Dhanesuan, J. A. Sharp, T. Blick, J. T. Price, and E. W. Thompson, Doxycycline-inducible expression of SPARC/ Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition, Breast Cancer Research and Treatment, vol. 75, no. 1, pp. 73-85, 2002.
54. B. Desai, T. Ma, and M. A. Chellaiah, Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion, The Journal of Biological Chemistry, vol. 283, no. 20, pp. 13856-13866, 2008.
55. C. Cougoule, V. Le Cabec, R. Poincloux et al., Three-dimensional migration of macrophages requires Hck for podosome organization and extracellular matrix proteolysis, Blood, vol. 115, no. 7, pp. 1444-1452, 2010.
56. H. Neubauer, Y. Yang, H. Seeger et al., The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells, Menopause, vol. 18, no. 8, pp. 845-850, 2011.
57. X.-D. Fu, L. Goglia, A.M. Sanchez et al., Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase, Endocrine-Related Cancer, vol. 17, no. 2, pp. 431-443, 2010.
58. D. Khaitan, U. T. Sankpal, B. Weksler et al., Role of KCNMA1 gene in breast cancer invasion and metastasis to brain, BMC Cancer, vol. 9, article 258, 2009.
59. J. Khan, L. H. Saal, M. L. Bittner, Y. Chen, J. M. Trent, and P. S. Meltzer, Expression profiling in cancer using cDNA microarrays, Electrophoresis, vol. 20, no. 2, pp. 223-229, 1999.
60. A. M. Stark, B. Anuszkiewicz, R. Mentlein, T. Yoneda, H. M. Mehdorn, and J. Held-Feindt, Differential expression of matrix metalloproteinases in brain-and bone-seeking clones of metastatic MDA-MB-231 breast cancer cells, Journal of Neuro-Oncology, vol. 81, no. 1, pp. 39-48, 2007.
61. D. Oxmann, J. Held-Feindt, A. M. Stark, K. Hattermann, T. Yoneda, and R. Mentlein, Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype, Oncogene, vol. 27, no. 25, pp. 3567-3575, 2008.
62. A. M. Stark, K. Tongers, N. Maass, H. M. Mehdorn, and J. Held-Feindt, Reduced metastasis-suppressor gene mRNAexpression in breast cancer brain metastases, Journal of Cancer Research and Clinical Oncology, vol. 131, no. 3, pp. 191-198, 2005.
63. A. J. Minn, G. P. Gupta, D. Padua et al., Lung metastasis genes couple breast tumor size and metastatic spread, Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 16, pp. 6740-6745, 2007.
64. X.-D. Fu, M. S. Giretti, L. Goglia et al., Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion, BMC Cancer, vol. 8, article 166, 2008.
65. X.-D. Fu, M. S. Giretti, C. Baldacci et al., Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton, PLoS ONE, vol. 3, no. 7, Article ID e2790, 2008.
66. Y. Pang and P. Thomas, Progesterone signals through membrane progesterone receptors (mPRs) in MDA-MB-468 and mPR-transfected MDA-MB-231 breast cancer cells which lack full-length and N-terminally truncated isoforms of the nuclear progesterone receptor, Steroids, vol. 76, no. 9, pp. 921-928, 2011.
67. K. B. Horwitz, W. W. Dye, J. C. Harrell, P. Kabos, and C. A. Sartorius, Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts, Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 15, pp. 5774-5779, 2008.
68. R. J. Craven, PGRMC1: a new biomarker for the estrogen receptor in breast cancer, Breast Cancer Research, vol. 10, no. 6, article 113, 2008.
69. H. Neubauer, S. E. Clare, W. Wozny et al., Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1, Breast Cancer Research, vol. 10, no. 5, article R85, 2008.
70. P. Thomas, Y. Pang, and J. Dong, Enhancement of cell surface expression and receptor functions of membrane progestin receptor α (mPRα) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors, Endocrinology, vol. 155, no. 3, pp. 1107-1119, 2014.
71. M. Guarino, Src signaling in cancer invasion, Journal of Cellular Physiology, vol. 223, no. 1, pp. 14-26, 2010.
72. J. H.Hanke, J. P. Gardner, R. L.Dow et al., Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck-and FynT-dependent T cell activation, The Journal of Biological Chemistry, vol. 271, no. 2, pp. 695-701, 1996.
73. c?src inhibitor PP1 is non-competitive against ATP, FEBS Letters, vol. 537, no. 1-3, pp. 47-52, 2003.
74. S. K.Mitra,D. A.Hanson, andD.D. Schlaepfer, Focal adhesion kinase: in command and control of cellmotility, Nature Reviews Molecular Cell Biology, vol. 6, no. 1, pp. 56-68, 2005.
75. J. J. Acosta, R. M. Muñoz, L. González et al., Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways, Molecular Endocrinology, vol. 17, no. 11, pp. 2268-2282, 2003.
76. V. C. Lin, E. H. Ng, S. E. Aw, M. G. Tan, E. H. Ng, and B. H. Bay, Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementaryDNA, Molecular Endocrinology, vol. 14 3 348-358 2000
77. X. Liu, Y. Chang, P. H. Reinhart, and H. Sontheimer, Cloning and characterization of glioma BK, a novel BK channel isoform highly expressed in human glioma cells, The Journal of Neuroscience, vol. 22, no. 5, pp. 1840-1849, 2002